<DOC>
	<DOCNO>NCT00482352</DOCNO>
	<brief_summary>This clinical trial study risk-group classification patient newly diagnose acute lymphoblastic leukemia . Developing risk-group classification guide may help doctor assign patient newly diagnose acute lymphoblastic leukemia treatment clinical trial .</brief_summary>
	<brief_title>Risk-Group Classification Patients With Newly Diagnosed Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Provide classification guide organize clinical laboratory data necessary assign patient newly diagnose acute lymphoblastic leukemia ( ALL ) specific treatment clinical trial . II . Provide administrative base capture classification data correlative study accompany current Children 's Oncology Group ( COG ) ALL treatment clinical trial . III . Provide central reference guide require research ALL study conduct local reference laboratory . IV . Provide mechanism optional banking leukemia germline specimens current future research . OUTLINE : Patients undergo blood collection bone marrow biopsy baseline end induction therapy immunophenotyping marker identification ; molecular testing translocation ; trisomy analysis fluorescence situ hybridization ( FISH ) ; DNA ploidy . Immunophenotype result obtain study use determine patient 's assignment specific treatment clinical trial ( consistent acute lymphoblastic leukemia ) . After completion induction therapy , patient follow twice annually .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>Newly diagnose acute lymphoblastic leukemia , define following : At least 25 % blast bone marrow Absolute blast count least 10,000/mm^3 , bone marrow aspiration perform No prior registration study</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>